Glimepiride/metformin - Sanofi

Drug Profile

Glimepiride/metformin - Sanofi

Alternative Names: Amaryl M; Metformin/glimepiride; Solosamet

Latest Information Update: 01 Jun 2015

Price : $50

At a glance

  • Originator Sanofi
  • Developer Handok Inc; Sanofi
  • Class Antihyperglycaemics; Biguanides; Small molecules; Sulfones; Sulfonylureas
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Glucose modulators; Insulinotropin agonists; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 01 Apr 2014 Sanofi completes the phase III LEGEND trial in Type 2 diabetes mellitus in Lebanon, Russia and Ukraine (NCT01699932)
  • 03 Oct 2013 Launched for Type-2 diabetes mellitus in South Korea (PO) some time prior to October 2013
  • 01 Jul 2013 Handok Pharmaceuticals is now called Handok Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top